|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
|
Mar 2019
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Apr 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey
|
Jun 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
|
Jun 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
|
Sep 2020
|
Leukemia & Lymphoma
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
